July 24, 2017 7:28 PM ET

Biotechnology

Company Overview of Kadmon Holdings, Inc.

Company Overview

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. Its lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase I...

450 East 29th Street

New York, NY 10016

United States

111 Employees

Phone:

212-308-6000

Fax:

646-666-7978

Key Executives for Kadmon Holdings, Inc.

Chief Executive Officer, President and Director
Age: 64
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice President
Age: 33
Total Annual Compensation: $600.0K
Chief Administrative, Compliance & Legal Officer, Executive Vice President and General Counsel
Age: 49
Total Annual Compensation: $600.0K
Compensation as of Fiscal Year 2016.

Kadmon Holdings, Inc. Key Developments

Kadmon Holdings, Inc. - Special Call

Research and Development Day

Kadmon Holdings, Inc. Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease

Kadmon Holdings, Inc. announced positive interim results from its ongoing Phase 2 clinical trial evaluating KD025, the Company’s Rho-associated coiled-coil kinase 2 (“ROCK2”) inhibitor, in patients with previously treated chronic graft-versus-host disease (“cGVHD”), a serious complication following allogeneic bone marrow or stem cell transplantation. In a preliminary analysis, KD025 demonstrated a favorable safety and tolerability profile in all patients and an overall response rate (“ORR”) of 71%. KD025-208 is an ongoing Phase 2 clinical trial evaluating the safety, tolerability and activity of KD025 in adults with steroid-dependent or steroid-refractory cGVHD and active disease. The dose-finding study includes 48 patients divided into three cohorts at different dose levels (KD025 200 mg QD, 200 mg BID and 400 mg QD), enrolled sequentially following a safety assessment of each cohort. In a preliminary analysis of data from the first cohort, KD025 200 mg QD (n=17), KD025 demonstrated clinically meaningful responses in cGVHD patients, with an ORR of 71% (12/17), which includes complete and partial responders. Of responders remaining on KD025 through week 24, 7 of 8 (88%) sustained responses. In addition to the 12 responders, two patients have stable disease and remain on KD025 through week 24. Overall clinical benefit (response and stable disease) occurred in 82% (14/17) of patients. 67%; 8/12 of responders saw an improvement in symptoms as measured by the Lee cGVHD Symptom Scale score. To date, no drug-related serious adverse events (SAEs) have been recorded, and no drug-related elevations in liver function tests have been observed. Importantly, 67% (8/12) of responders had reduction of steroid doses and 67% (4/6) of patients had reduction of tacrolimus doses.

Kadmon Holdings, Inc. Presents at JMP Securities Life Sciences Conference 2017, Jun-20-2017

Kadmon Holdings, Inc. Presents at JMP Securities Life Sciences Conference 2017, Jun-20-2017 . Venue: St. Regis Hotel, 2 East 55 Street, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 8, 2017
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kadmon Holdings, Inc., please visit www.kadmon.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.